MIM
LAB icon

MetLife Investment Management’s Standard BioTools LAB Stock Holding History

MetLife Investment Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-86,220
Closed -$79.3K – 2922
2026
Q1 		$79.3K Sell
86,220
-38,668
-31% -$46.8K ﹤0.01% 2624
2025
Q4 		$160K Sell
124,888
-28,041
-18% -$37.7K ﹤0.01% 2386
2025
Q3 		$199K Sell
152,929
-28,333
-16% -$37.1K ﹤0.01% 2318
2025
Q2 		$218K Buy
181,262
+60,285
+50% +$66.8K ﹤0.01% 2145
2025
Q1 		$131K Sell
120,977
-62,405
-34% -$87.6K ﹤0.01% 2403
2024
Q4 		$321K Buy
183,382
+40,057
+28% +$74.6K ﹤0.01% 2033
2024
Q3 		$277K Buy
143,325
+66,410
+86% +$130K ﹤0.01% 2119
2024
Q2 		$136K Buy
+76,915
New +$188K ﹤0.01% 2455
2022
Q2 		– Sell
-35,462
Closed -$127K – 2887
2022
Q1 		$127K Buy
35,462
+26,153
+281% +$90.3K ﹤0.01% 2574
2021
Q4 		$36.5K Sell
9,309
-20,592
-69% -$96.4K ﹤0.01% 2474
2021
Q3 		$197K Hold
29,901
– – ﹤0.01% 2113
2021
Q2 		$184K Buy
29,901
+23,924
+400% +$128K ﹤0.01% 2220
2021
Q1 		$27K Sell
5,977
-26,759
-82% -$147K ﹤0.01% 2298
2020
Q4 		$196K Sell
32,736
-3,119
-9% -$20.5K ﹤0.01% 1995
2020
Q3 		$266K Hold
35,855
– – ﹤0.01% 1686
2020
Q2 		$144K Buy
+35,855
New +$125K ﹤0.01% 2075
2019
Q4 		– Sell
-32,475
Closed -$150K – 2317
2019
Q3 		$150K Hold
32,475
– – ﹤0.01% 2101
2019
Q2 		$400K Sell
32,475
-15,837
-33% -$202K ﹤0.01% 1614
2019
Q1 		$642K Buy
+48,312
New +$509K ﹤0.01% 1920
2018
Q2 		– Sell
-20,596
Closed -$120K – 2199
2018
Q1 		$120K Hold
20,596
– – ﹤0.01% 2128
2017
Q4 		$121K Buy
+20,596
New +$113K ﹤0.01% 2171

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

MetLife Investment Management's LAB Position: Q2 2026 in Review

MetLife Investment Management sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 86,220 shares — an estimated $79.3K sold.

MetLife Investment Management first reported a position in LAB in Q4 2017 and held it in 21 quarters. The position peaked at $642K in Q1 2019. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • MetLife Investment Management reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
  • MetLife Investment Management sold 86,220 Standard BioTools shares in Q2 2026, an estimated $79.3K.
  • MetLife Investment Management first reported a position in Standard BioTools in Q4 2017 and held it in 21 quarters.
  • MetLife Investment Management's Standard BioTools position peaked at $642K in Q1 2019.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.